Merck Acquires Ariad Cancer Drug | May 10, 2010 Issue - Vol. 88 Issue 19 | Chemical & Engineering News
Volume 88 Issue 19 | p. 21 | Concentrates
Issue Date: May 10, 2010

Merck Acquires Ariad Cancer Drug

Department: Business
Keywords: drug discovery, cancer

Merck & Co. has acquired development and worldwide commercialization rights for ridaforolimus, an Ariad Pharmaceuticals drug now in Phase III trials as a treatment for metastatic soft-tissue and bone cancers. Merck will pay Ariad $50 million up front and up to $514 million in milestone payments. The two firms started collaborating on the drug, a small-molecule inhibitor of the cell proliferation protein mTOR, in July 2007. Ariad says the deal will allow it to devote resources to two other cancer therapies in its pipeline.

 
Chemical & Engineering News
ISSN 0009-2347
Copyright © American Chemical Society

Leave A Comment

*Required to comment